
Press Release - For Immediate Release

AsiaMedic strengthens core business, records net profit of S\$113,000 for FY2013

- **Revenue rose 24% to S\$14.7 million on healthy demand for core business and maiden contributions from new business units**
- **Net profit improved 162% y-o-y to S\$113,000**

Singapore, 28 February 2014 – SGX Catalist-listed AsiaMedic Limited (“AsiaMedic” or the “Group”, “亚美德科医疗集团”), a premier healthcare provider in Asia, is pleased to announce a positive set of results for the financial year ended 31 December 2013 (“FY2013”). AsiaMedic recorded revenue of S\$14.7 million in FY2013, an improvement of 24% over previous year’s S\$11.9 million. The Group posted net profit attributable to shareholders of S\$113,000 in FY2013, representing a 162% increase over S\$43,000 in FY2012.

AsiaMedic’s core business consisting of diagnostic imaging and wellness management continues to strengthen Group revenue in FY2013, witnessing an increase of 11.5% in revenue to S\$12.7 million. In addition, the Group received positive maiden contributions from Complete Healthcare International (“CHI”) and Astique The Aesthetic Clinic (“Astique”), which were acquired in FY2013.

As for corporate developments, in May 2013, AsiaMedic acquired an 80% equity stake in CHI, which is a multi-doctor medical practice that is popular among the expatriate community in Singapore. The Astique acquisition was completed in June 2013, with AsiaMedic taking up a 70% equity stake. Following that, the Group partnered Cryoviva International to establish Cryoviva Singapore, which has entered the local cord blood banking scene as the third private sector player. AsiaMedic holds a 25% in the joint venture, with an option to raise its stake to 49% within two years.

At its flagship centre, AsiaMedic has expanded its operating space by another 8,000 square feet, as the Group secured additional floor space on the 10th floor of Shaw House. The Group added a third Magnetic Resonance Imaging (MRI) scanner on this new floor, boosting its capacity by 50%. Other technological upgrades include a new Computerized Tomography (CT) machine and digitized X-Ray and Mammography imaging systems which serve to increase throughput. To meet higher patient load and maintain service standards, AsiaMedic has increased headcount as well as training expenditures. Marketing expenditure has also been raised to drive sales and strengthen the Group’s corporate branding.

Excluding one-off legal and professional fees, overseas business development costs, impairment of loans, as well as start-up costs of Cryoviva Singapore, the earnings before interest, taxation, depreciation and amortisation (EBITDA) would be approximately S\$1.8 million for FY2013 compared against S\$1.5 million FY2012.

The increase in 27% in total operating expenses to S\$15.4 million from previous year was mainly due to the new acquisitions and operational improvements made. The Group obtained bank financing for the acquisition of CHI and capital expenditure, resulting in the higher finance cost of 79% to S\$72,783. Current ratio (current assets/current liabilities) remains healthy at 1.6 times while AsiaMedic continues to generate positive operating cashflow. Total cash holdings in FY2013 decreased to S\$7.2 million from S\$9.2 million in FY2012. Bulk of the funds was spent in the acquisitions, renovation works for the new floor and new medical equipment.

Dr. Wong Weng Hong, CEO of AsiaMedic, said: *"We are pleased with our expansion progress in FY2013, in view of the series of acquisitions, a new joint venture and organic expansion. Apart from expanding our range of services, we have also identified cord blood banking to be a business that holds good potential as medical science in this field continues to progress.*

Our acquisition strategy has been encouraging, as seen from the positive maiden contributions from CHI and Astique. Already we have hired more physicians and expanded operating space for these new acquisitions. Furthermore, by tapping on the expanded pool of customers under the Group, we also observed higher revenues from our outlets under imaging and wellness as a result of cross referrals.

We believe that business environment will remain favourable in the long term, in view of the aging population, growing health awareness as well as the resilient medical tourism. That said, we will remain focused on strengthening our core services and explore opportunities to expand locally and regionally."

- END -

This announcement has been prepared by the Company and reviewed by the Company's sponsor, Asiasons WFG Capital Pte Ltd (the "Sponsor"), for compliance with the Listing Manual (Section B: Rules of Catalist) of the Singapore Exchange Securities Trading Limited (the "SGX-ST"). The Sponsor has not independently verified the contents of this announcement including the accuracy or completeness of any of the information disclosed or the correctness of any of the statements made, opinions expressed or reports contained in this announcement. This announcement has not been examined or approved by the SGX-ST. The SGX-ST and the Sponsor assume no responsibility for the contents of this announcement including the correctness of any of the statements made, opinions expressed or reports contained in this announcement.

Contact person for the Sponsor: Ms Pauline Sim (Registered Professional, Asiasons WFG Capital Pte Ltd)
Address: Cross Street, #03-54/61 China Square Central, Singapore 048421
Telephone number: (65) 6319 4954

Media & Investor Contacts

Mr. Andreas Chan

Direct Line: +65 6517 8771

Mobile: +65 9857 1123

Email: andreas.chan@shareinvestor.com

Mr. Andy Lin

Direct Line: +65 6517 8775

Mobile: +65 9651 7743

Email: andy.lin@shareinvestor.com

About AsiaMedic Limited (Bloomberg: AMAT:SP / Reuters: ASIM.SI)

Headquartered in Singapore and listed on the Catalist Board of the Singapore Stock Exchange, AsiaMedic Limited is a premier healthcare provider that focuses on the management of clinical services in the fields of disease prevention, early illness detection and advanced diagnostics. Its team of highly qualified and reputable professionals provides clinical and management services both in Singapore and overseas.

The core services provided by AsiaMedic include but are not limited to health-risk assessments and screening, general and subspecialty imaging such as MRI and CT Scans for cardiovascular, neuroradiological, ENT and musculoskeletal imaging; PET/CT imaging for diagnosis, staging, localisation and monitoring progress of cancer.

In 2013, the Group augmented its healthcare service portfolio through acquiring Astique The Aesthetic Clinic and Complete Healthcare International. The Group also expanded its presence in the region by providing tele-radiology services to two hospitals in Myanmar. In addition, it operates a post-natal care centre and a medical centre in China. AsiaMedic partnered Cryoviva International to establish Cryoviva Singapore, which has entered the local cord blood banking scene as the third private sector player.

Driven by its commitment to the core values of competence, care, convenience and collaboration, AsiaMedic has built up a strong brand name for delivering positive patient outcomes and high-quality care for its patients from Singapore and around the region.

As an endorsement of its strengths and track record in the regional healthcare services industry, AsiaMedic was awarded two high-profiled turnkey projects in Abu Dhabi by Mubadala Healthcare, a division of Mubadala Development Co. and owned by the Government of the Emirate of Abu Dhabi. The projects were successfully completed and handed over in early 2012.

Having tested and proven its healthcare services business model in Singapore and the region, AsiaMedic is developing more innovative healthcare services in selected markets for its next stage of growth.